MedTrace Logo

Pancreatic Duodenal Homeobox Factor-1 (PDX-1) and Neurogenin-3 (NGN-3) in Gestational Diabetes

NCT03964987 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2019-05-28

No results posted yet for this study

Summary

Introduction: Depletion of the ability of the cells ß to secrete the amount of insulin required by pregnancy, increasing the risk of develop Gestational Diabetes Mellitus (GDM). The aim was to contrast the messenger RNA (mRNA) expression of the pancreatic duodenal homeobox factor-1 (PDX-1) and Neurogenin-3 (Ngn-3) in peripheral blood of pregnant women with GDM versus women with normal pregnancies.

Material and methods: This was a prospective, clinical and cross-sectional study, conforming two groups of pregnant women: a) patients with a healthy gestation and b) patients with GDM. Besides anthropometry and routine laboratorial test, real-time polymerase chain reaction (Real-Time PCR), was used to quantify the expression of PDX-1 and NGN-3.

Conditions

  • Gestational Diabetes

Sponsors & Collaborators

  • Universidad Autonoma del Estado de Mexico

    collaborator OTHER

  • Materno-Perinatal Hospital of the State of Mexico

    lead OTHER

Principal Investigators

  • Hugo Mendieta Zerón, PhD. · Maternal-Perinatal Hospital "Mónica Pretelini Sáenz"

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2018-08-30
Completion
2018-12-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03964987 on ClinicalTrials.gov